HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, on 5 February, GIC Private Limited made its first equity investment in Ascletis Pharma (01672) by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 2026年2月6日报道,根据香港联交所2月6日披露的文件,新加坡政府投资公司(GIC Private Limited)于2月5日首次入股歌礼制药(01672),以每股均价12.18 港元 买入 64,128,000 股普通股股份,合计涉资约7.81 亿港元,折合约1亿美元。入股完成后,GIC持有歌礼制药64,128,000股股份,占公司已发行股本约6.42%,正式跻身公司主要机构股东行列。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Currently, digital transformation has become the core proposition of global industrial upgrading, and the manufacturing industry is also undergoing a disruptive transformation from being “experience-driven” to “data intelligence-driven”. In this process, the deep integration of artificial intelligence and industrial scenarios has become the key to resolving manufacturing complexity and unleashing productivity. The introduction of the Action Plan for Integrating and Empowering Industrial Internet and Artificial Intelligence by MIIT further marks the upgrade of “AI + Manufacturing” from an optional pathway to a mandatory one, giving rise to a blue ocean of value worth tens of trillions.As a deep participant and leader in the digital and intelligent transformation of the manufacturing industry, COSMOPlat IoT Technology Co., Ltd. (“COSMOPlat”) has, based on its profound understanding of massive data and complex scenarios in the industrial field, built a full-stack AI technology system that includes training and inference platform, large models, intelligent agent development and application platforms. This has not only redefined the implementation path of industrial digitalization and intelligentization, but also continuously strengthened its technical barriers in industrial practice, building a solid and difficult-to-replicate moat, and is expected to benefit deeply from the dividends of industrial digital and intelligent transformation and development. On January 30, COSMOPlat submitted a listing application to the HKEX, embarking on a new chapter of value realization.AI Restructuring Industrial Digitalization: Full-stack Architecture and Flywheel Effect Build Core BarriersIn traditional perception, the industrial internet is a platform for data connection and circulation, and its technical boundaries remain more at the levels of equipment access, data collection, and process visualization. However, through its original “space-air-ground integrated” full-stack AI technology system, COSMOPlat has deeply embedded “AI+” into its technology architecture, achieving an intelligent closed-loop across the entire chain from perception and decision-making to execution, transforming data into intelligent decision-making capabilities, completely overturning the technology logic of the traditional industrial internet, and building an inimitable technology moat.At the “space” level, COSMOPlat utilizes “COSMOMind”, the first domestic vertical large model based on an industrial internet platform, as its decision-making hub. “COSMOMind” deeply integrates Haier Group's over 40 years of manufacturing knowledge, as well as expert models and high-quality multimodal datasets accumulated on the COSMOMind Industrial Big Data. It possesses significant advantages in industrial scenario analysis, knowledge Q&A, and logical reasoning, with a retrieval accuracy rate of up to 93% in industrial knowledge fusion and retrieval. Through the "one industry, one model" strategy, COSMOPlat has developed industry-specific large models for enterprises in home appliances, energy and chemicals, energy and carbon industries, providing intelligent decision-making support for major industrial scenarios including research and development design, production manufacturing, operation services and dual-carbon management.Industry intelligent agents and industrial software serve as the “air link”, transforming the decision-making instructions of large models into more flexible human-machine interaction methods and more efficient execution capabilities. As of the Latest Practicable Date, COSMOPlat has developed 57 industrial intelligent agents covering over 40 core scenarios across 3 major industries, which can handle key industrial functions such as process optimization, equipment management, and smart energy and carbon, helping customers achieve intelligent control of industrial processes, shorten process parameter adjustment cycles, improve equipment operation and maintenance efficiency, and reduce production energy consumption and energy costs.At the “ground” level, intelligent terminals and automation equipment, acting as the executing limbs, transform AI capabilities into actual production actions and integrate them into the entire manufacturing process, achieving efficient synergy among data, equipment and scenarios, driving industrial AI from isolated intelligent applications to domain-wide intelligence, creating value-added throughout the entire process for customers across various industries, and maximizing the release of data value.Relying on the “space-air-ground integrated” full-stack AI technology system, COSMOPlat has achieved full-link intelligence across “perception-analysis-decision-execution-feedback”, forming a unique flywheel effect of “data accumulation—model refinement—intelligent agent deployment—data reinforcement”, achieving self-reinforcement and a virtuous cycle where “more data is generated through use, models become more precise through use, and intelligent agent scenarios become broader through use”, enabling COSMOPlat's AI capabilities to continuously evolve in practice and building a solid technology barrier.Practical Evidence: AI Empowerment from Concept to Significant Scenario Implementation ResultsThe value of technology must ultimately be tested by the market. COSMOPlat has demonstrated through numerous benchmark cases that its AI empowerment has moved beyond the “proof of concept” stage and is capable of delivering tangible economic benefits to enterprises.In the petrochemical industry, COSMOPlat has developed the world's first petrochemical large model covering the entire industry chain, entire ecosystem chain, and entire value chain, which has been implemented in a large-scale petrochemical enterprise. Based on the model, the Company has developed 38 intelligent agents, such as the dynamometer intelligent assistant and the aldehyde separation tower process optimization agent, covering scenarios such as oilfield extraction, oil and gas refining and chemical processing, and production safety, with an average efficiency increase of 20%. Taking the dynamometer intelligent assistant as an example, based on the professional capabilities of whole-network search and the COSMOMind, this intelligent agent can “read and understand” dynamometer data of industrial equipment such as deep well pumps, accurately identify equipment failures and provide disposal suggestions, improving the efficiency of oil well equipment failure diagnosis and disposal by more than 50%; the aldehyde separation tower process optimization assistant integrates historical data and expert knowledge, enabling dynamic identification and adjustment suggestions for key parameters, providing decision-making assistance for operators, and significantly enhancing quality control precision and the product first-time conversion rate; the intelligent oil blending assistant quickly generates optimal blending schemes through interpolation algorithms and non-linear programming models, balancing product performance with green production requirements, fully validating the practical value of AI in the heavy chemical industry.In core manufacturing scenarios, COSMOPlat integrates AI technology throughout the entire chain of R&D, production, operation and maintenance. On the R&D side, taking a home appliance interconnected factory selected as a world “lighthouse factory” as a typical example, an AIGC virtual design assistant was introduced. Based on massive user preference data and an expert design asset library, it generated core solutions for three-drum washing machines. By simulating inner drum operation scenarios in advance to construct a dynamic balance optimization model, it solved the industry pain point of “collisions and interference” during multi-drum operation at the source; on the production side, the injection molding industrial intelligent agent, through deep learning of injection molding professional knowledge, equipment operation data, and process data, etc., precipitated the debugging methods that previously existed only in the minds of process technicians into various intelligent algorithms, ultimately forming professional injection molding knowledge Q&A and automated process parameter recommendation capabilities, building the most powerful “industrial brain” in the field of injection molding.In the energy sector, COSMOPlat’s energy-carbon model (COSMOMind for energy-carbon) is the first energy-carbon model originating from sustainable lighthouse factory practices. Based on this model, COSMOPlat offers enterprises and industrial park users an Energy-Carbon Management Platform and end-to-end smart-energy solutions, helping customers lower energy cost, improve utilization and advance green manufacturing. These cross-industry and multi-scenario success stories strongly demonstrate the practical effectiveness and replicability of COSMOPlat’s AI solutions.From an industrial cycle perspective, as the manufacturing system grows increasingly complex and cost and efficiency constraints intensify, enterprises' demand for end-to-end digital and intelligent transformation will continue to rise, ensuring long-term certainty in industry development.COSMOPlat has pioneered the “space-air-ground integrated” technology system centered on large industrial models, with intelligent agents deeply embedded in production processes. This delivers a closed loop of perception, decision-making, and execution. Through multi-industry and multi-scenario validation, it demonstrates that AI possesses the capability to continuously generate industrial value. As application scenarios continue to expand, intelligent agents scale up, and the data flywheel effect intensifies, COSMOPlat is poised to translate its technological leadership into heightened platform stickiness and greater value per customer. Riding the wave of digital transformation, it is unlocking greater potential for value growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – On February 6, Distinct Healthcare Holdings Limited ("Distinct Healthcare" or the "Company", Stock Code: 2677.HK), a leading player in China's mid-to-high-end consumer healthcare services market, was successfully listed on the main board of the Hong Kong Stock Exchange, emerging as a high-quality and rare private healthcare gem in the Hong Kong stock market. This marks the beginning of a new chapter in the Company's scaled and high-quality development.On its debut, Distinct Healthcare delivered a standout debut, opening sharply higher at HK$81 per share (a 35.23% premium to the offer price), well above the offer price—an indication of strong capital market recognition of the Company's growth potential. The active trading and high investor enthusiasm further corroborate the market's firm confidence in the consumer healthcare services sector and the Company's core value.Possessing a Large Customer Base with Continuously Improving ProfitabilityAs the third-largest provider of private mid- to high-end healthcare service in China, Distinct Healthcare has always adhered to its patient-oriented core principle, placing patient well-being at the forefront. This approach has enabled the Company to gradually build a large and high-quality patient base, leading the industry in both user scale and return rate.From 2022 up to the eight months ending 31 August 2025, the total number of patients served by its healthcare institutions in China rose from 162,393 to 212,180, and the total number of paid patient visits of its healthcare service institutions and tele-healthcare service platform grew from 529,829 to 642,132.Patient loyalty has continued to rise, with the patient return rate steadily climbing. In 2022, 2023, 2024 and the eight months ended 31 August 2025, the patient return rates reached 75.7%, 78.2%, 80.0% and 82.7%, respectively. This robust growth is a strong testament to the market and patients' high recognition of Distinct Healthcare's service quality.Leveraging its large and high-quality customer base and the advantages of its standardized medical services, Distinct Healthcare has achieved steady business growth "without relying on medical insurance subsidies or excessive marketing expenditure". Financial data shows the Company's total revenue increased steadily from RMB473 million in 2022 to RMB959 million in 2024, doubling its revenue in two years and achieving a compound annual growth rate (CAGR) of 42.3%, demonstrating strong growth momentum.In terms of profitability, the Company achieved a critical milestone by turning profitable in 2024, with an adjusted net profit of RMB10.7 million. This represents a qualitative leap from scale-driven growth to profitability-driven growth.Strong Line-up of Cornerstone Investors and Clear Strategic Plan Support High-Quality DevelopmentDistinct Healthcare has attracted a strong roster of cornerstone investors in this IPO, including Health Vision, Kingmed Diagnostics, Mininglamp Technology, and Galaxy Dynasty. Together, they subscribed for a total of approximately HK$90.7876 million. The active participation of these renowned, high-quality institutional investors fully reflects their high recognition of Distinct Healthcare's core competitiveness, business model, and future development prospects, and will also provide powerful resource support and brand endorsement for the Company's subsequent development, helping it to further expand its industry influence.Regarding the use of IPO proceeds, Distinct Healthcare has formulated a clear strategic plan to ensure the proceeds are effectively deployed to support the Company's high-quality growth. Approximately 35% of the net proceeds will be allocated to digitalization and intelligent upgrades. By building a professional talent pool for medical AI applications, establishing strategic partnerships with leading research institutions and technology companies and making external procurements, while leveraging internal IT and data technology departments to iteratively optimize existing IT systems, the Company will deploy advanced AI technologies, optimize medical service workflows and enhance diagnostic efficiency as well as operational effectiveness.Approximately 30% of the net proceeds will be used for service network expansion and upgrades, primarily focusing on enhancing the diagnostic environment and equipment at existing medical service institutions. It will also advance the layout of new institutions, including relocating an existing institution in Shenzhen and establishing new institutions in key cities such as Hangzhou and Shanghai, thereby further expanding and improving service coverage in key domestic regions.Approximately 25% is earmarked for strategic mergers and acquisitions, acquire high-performing medical service institutions with strong synergies in first-tier and new first-tier cities when suitable opportunities arise, aiming to rapidly expand market share and strengthen regional competitiveness. The remaining approximately 10% will be used as working capital and for general corporate purposes, providing stable financial support for daily operations and business expansion.This clear strategic roadmap not only charts a clear course for the Company's future growth, effectively enhancing its core competitiveness and sustainability, but will also further reinforce its leading position in China's private mid-to-high-end healthcare sector. It will help propel the Company to new heights, achieving its long-term goals of scaled and high-quality development.This successful listing on HKEX represents a significant milestone in Distinct Healthcare's development journey, marking its official entry into a new phase driven by both "capital and industry". It will further elevate the Company's brand influence and financing capabilities, injecting powerful momentum for its future growth.Moving forward, Distinct Healthcare will remain true to its founding aspirations, staying focused on the mid-to-high-end healthcare services segment. It will continue to enhance medical service quality and patient experience, further unlock its growth potential and deliver sustainable long-term returns to its shareholders. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – On 6 February, Muyuan Foods Co., Ltd. ("Muyuan Foods" or the "Company", Stock Code: 2714.HK), a global leader in the pork industry, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today, marking the beginning of a new chapter in the Company's international development.Powerful Cornerstone Investors Underscore Muyuan’s Industry LeadershipFor this Hong Kong IPO, Muyuan Foods successfully attracted a prestigious lineup of cornerstone investors, including Charoen Pokphand Foods, Wilmar International Limited (Wii Pte. Ltd. and HPRY), Sinochem Hong Kong, Hong Kong Henan AgriInternational, FIL Investment, RBC Global Asset Management (Asia) Limited and Ping An Life Insurance Company of China, Ltd., and other renowned institutions—14 in total—with combined subscription amounting to US$685 million. This formidable cornerstone investor group not only provides the Company with stable financial support but also brings abundant industrial resources and an international perspective, laying a solid foundation for its subsequent global expansion and valuation enhancement.As a technology-driven pork industry leader, Muyuan Foods has deep expertise cultivated over many years in the industry and has established a uniquely advantageous vertically integrated business model. Its operations comprehensively cover the entire pork industry chain, including hog breeding, hog farming, feed production, as well as slaughtering and meat production. Leveraging synergistic advantages across the entire chain, the Company has steadily maintained its leadership position in the hog farming industry.According to statistics from Frost & Sullivan, since 2021, measured by hog production capacity and hog sales volume, Muyuan Foods has become the world's largest hog farming enterprise. Its hog sales volume has ranked first globally for four consecutive years, solidifying its position as the industry leader. In terms of market share, the Company's global market share steadily increased from 2.6% in 2021 to 5.6% in 2024. As of 2024, this market share already exceeded the combined market share of the world's second to fourth largest participants in the hog farming industry, further widening the gap with peers and continuously highlighting its core competitiveness.Steady Earnings Growth Maintained; Active Overseas Market Expansion Strengthens CompetitivenessRelying on its full industry chain layout and efficient operational management, Muyuan Foods has maintained steady earnings growth in recent years, with profitability continuously improving, demonstrating the Company's operational resilience through solid business data. Data shows that the Company's revenue scale grew steadily from RMB124.826 billion in 2022 to RMB137.947 billion in 2024. Net profit surged significantly from RMB14.933 billion in 2022 to RMB18.925 billion in 2024, indicating remarkable growth and continuously optimized profitability. Entering 2025, the Company's growth momentum further accelerated. In the first nine months of 2025, the Company achieved operating revenue of RMB111.790 billion, a year-on-year increase of 15.5%, and realized a net profit of RMB15.112 billion, a substantial year-on-year increase of 34.4%. The double-digit growth in both revenue and net profit fully demonstrates the Company's strong development momentum and favorable profit outlook.While consolidating its leading position in the domestic market and achieving rapid self-development, Muyuan Foods has consistently anchored its global development strategy, actively expanding into overseas markets. Using the export of technology and equipment as a key approach, it empowers the upgrading of the global hog farming industry and builds an international farming ecosystem. In 2024, the Company entered into a deep strategic partnership with BAF Vietnam Agriculture, providing services including hog house design, biosecurity management, odor control solutions and smart hog farming to help its partner optimize farming efficiency, reduce operational costs, and practice environmentally responsible farming.The smooth progress of this cooperation marks a crucial first successful step for Muyuan Foods in its global layout, accumulating valuable experience for subsequent overseas market expansion. On the other hand, leveraging the vast potential of overseas markets, Muyuan Foods will further achieve optimized resource allocation and efficient synergy on a global scale, continuously broadening its corporate growth boundaries and diversifying profit sources, thereby solidifying its core advantages and enhancing comprehensive competitiveness.Overall, the successful listing in Hong Kong not only signifies that Muyuan Foods has formally entered a new stage of internationalized development, establishing an important bridge connecting global capital and resources, but also indicates that the Company's operational management level, industry competitiveness, and development potential have gained broad recognition from the international capital market. In the future, Muyuan Foods will seize this listing opportunity, adhere to the philosophy of technology-driven and green development, continue to deepen its involvement in the entire pork industry chain, constantly strengthen its core competitiveness, steadily advance its global layout, further consolidate its position as the global leader in the hog farming industry, and open up broader growth space. Its future development is worthy of market anticipation. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
(SeaPRwire) - 上门取件和专业的织物护理服务帮助居民和企业更轻松地处理阿联酋的洗衣事务。迪拜,阿拉伯联合酋长国 2026年2月5日 - Laundry Khalas,一家阿联酋专业的洗衣服务提供商,正在迪拜、沙迦和阿治曼扩展其便捷的洗衣解决方案。该公司通过结合可靠的清洁服务与上门取件和及时送达,致力于让家庭和企业的日常洗衣更简单。 在当今忙碌的生活方式中,许多人发现很难跟上洗衣、熨烫以及处理被子、窗帘或制服等大件物品的日常任务。Laundry Khalas 通过提供灵活的调度和专业的服装护理来满足这一需求,旨在节省时间同时保持织物质量。 该公司提供一系列服务,包括洗涤和折叠洗衣、干洗、熨烫和压烫、被子和毯子清洁、窗帘和家具清洁、餐厅亚麻布服务以及工作服或制服清洗。这些服务同时支持住宅客户和商业部门,如酒店业、公司办公室和医疗保健设施。 阿联酋的气候,由于其炎热、潮湿和灰尘暴露,通常需要更频繁的织物护理以保持卫生和舒适。专业的洗衣服务有助于延长服装寿命,提高清洁度,并确保对不同织物类型的正确处理。Laundry Khalas 使用现代化的清洁方法和训练有素的专业人员,在保护织物的同时提供一致的结果。 客户可以通过公司网站了解更多关于可用服务或直接安排取件: 随着对便捷洗衣解决方案的需求不断增长,Laundry Khalas 致力于使专业的洗衣护理更加便捷,同时保持可靠性、质量和客户便利性。媒体联系Laundry Khalas+971 503841660 来源 :Laundry Khalas本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 在中国资本市场,牧原股份(2714.HK)是一家伴随争议成长的公司:猪周期的波动、重资产投入、阶段性高负债的经营状态,曾多次成为市场热议的焦点。但拉长时间周期,这些曾被市场讨论的「争议点」,已经开始转化成为牧原股份难以复制的核心竞争壁垒。所谓的重资产投入,并非盲目扩张,而是精准布局生猪育种、饲料生产、养殖、屠宰肉食全产业链以及智慧养殖的必要投资,最终沉淀为行业领先的成本优势与抗周期能力。2月6日,这家深耕生猪产业三十余年的龙头企业,正式登陆香港联交所。此次上市不仅标志着牧原股份成功搭建了「A+H」双资本平台,获得了更广阔的国际融资渠道,更意味着公司向着「全球养殖巨头」的目标迈出了关键一步。行业变局下的领航者:重构生猪产业发展新范式生猪产业作为关乎民生的基础产业,长期以来受「猪周期」波动、疫病防控等痛点困扰。但近年来,随着环保政策趋严、规模化养殖提速、消费需求升级,行业正迎来结构性变革——产业集中度持续提升成为必然趋势。据行业数据显示,于2024年规模化生猪养殖的渗透率达到70.1%,且其预期将于2029年达到79.4%,但相较于美国2024年90%以上的集中度,仍有巨大提升空间。牧原股份率先突破传统养殖模式的局限,构建了覆盖生猪育种、生猪养殖、饲料生产、屠宰肉食的全产业链垂直一体化体系,实现了「从农场到餐桌」的全流程可控。这种模式不仅彻底解决了传统养殖「上下游脱节、成本高企、质量难控」的痛点,更形成了强大的协同效应——饲料环节为养殖环节提供低成本、高质量的饲料供应,养殖环节为屠宰环节提供稳定的生猪来源,屠宰环节则通过消费需求反哺育种与养殖环节,形成死循环发展。更为关键的是,牧原股份将科技深度融入产业全链条,从自主研发的空气过滤猪舍、智慧巡检机器人,到数据驱动的基因选育平台、优化豆粕日粮技术,牧原以技术创新持续优化养殖效率、降低成本、提升质量。截至2025年9月30日止九个月,公司平均PSY达到约28,领先行业平均水平;育肥猪日增重约841克,亦领先同业;年均完全成本进一步降至每公斤人民币12元,继续巩固其在养殖成本端的竞争壁垒。于往绩记录期间,牧原股份累计拥有专利超1700项,其降氨除臭解决方案、优化豆粕日粮技术更是被国家相关部门作为典型案例向全行业推广,引领生猪产业向智慧化、绿色化、标准化转型。价值投资的优选目标:稳健底色与长期回报兼具牧原的吸引力,不仅来自其强大的业务模式和技术优势,同样也源于其日益稳健的财务表现和清晰的股东回报政策。盈利端,尽管生猪行业具有明显的周期性特征,但牧原股份极致的成本控制能力,在过去十年中展现了超越周期的盈利能力。2014-2024年间,公司净利润复合年均增长率达到72.7%,平均年净利润率19.0%,是全球前十猪肉上市企业中唯一一家同期平均净利润率超15%的企业。即使在行业低谷期,公司仍能保持稳健盈利,展现出极强的盈利韧性。财务层面,随着前期大规模的产能建设逐步完成,牧原正进入「投资回报期」。2022-2024年累计经营活动现金流入净额已1.6倍覆盖累计资本性支出,2025年前三季度这一比例进一步提升至3.9倍。充裕的现金流不仅为公司继续扩大竞争优势提供了资金支持,也为持续分红和债务结构优化创造了条件。截至2025年三季度末,公司资产负债率为55.50%,负债总额较年初已下降约98亿元。此外,牧原股份始终重视股东回报,2022年至2025年前9个月累计派息166亿元。公司最新制定的2024-2026年股东回报规划,明确承诺每年以现金方式分配的利润由不少于当年实现的可供分配利润的40%。这一明确的回报政策,不仅体现了公司对股东的责任意识,也为其未来股价提供了重要的价值支撑。全球化布局启新程:从中国龙头到全球标杆此次港股上市,标志着牧原股份全球化战略进入新的发展阶段。在全球猪肉消费格局变化的背景下,公司正在从中国的龙头企业向世界级农业企业迈进。目前,牧原股份的海外布局已取得实质性突破,展现出强劲的落地能力。2024年与越南BAF农业有限公司达成战略合作,迈出海外拓展第一步;2025年8月,与正大集团签署战略合作协议,双方将围绕战略规划、业务整合与全球化布局等方面开展全方位合作,共同探索全球市场的巨大潜力;2025年9月,与BAF合作升级,双方合作在越南总投资32亿元的高科技楼房养殖项目,规划年出栏规模达160万头,展现了公司将国内成熟的养殖管理模式向海外复制的能力。按照牧原的战略规划,未来公司在通过技术服务、设备销售等轻资产模式进入海外市场的基础上,也会结合各地实际情况,选择多种方式开展国际化业务,包括在海外新建产能、开展有针对性的收并购等模式,海外业务的潜力增长将为公司带来对抗猪价风险的硬实力,提供新的增长空间。从行业发展趋势来看,长期稳态下,生猪养殖产业整体将保持合理的利润水平,而行业具备养殖管理和成本优势的企业望保持较好盈利能力。牧原股份养殖规模领先,养殖成本优势持续增强,盈利能力领先同行,此外,公司积极海外拓潜,向全球养殖巨头成长演化,展现出难得的确定性和成长性。随着公司在全产业链深耕、市场拓展方面的持续投入,其内在价值有望在未来几年得到进一步释放。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
(SeaPRwire) - 该公司将在定于2026年4月21日至23日举行的全球行业盛会上展示其药品包装技术古吉拉特邦艾哈迈达巴德2026年2月5日电 - USA Pack Machines LLC宣布将参加INTERPHEX 2026。这是一场领先的制药和生物技术制造展览会,定于2026年4月21日至23日在纽约Jacob K. Javits会议中心举行。该活动汇聚了来自制药开发和制造生态系统各领域的专业人士,为技术交流、教育和行业合作提供了一个平台。 USA Pack Machines LLC是Harikrushna Machines Pvt. Ltd.(印度)在美国的分支机构。自1999年以来,Harikrushna Machines Pvt. Ltd.作为液体加工和包装解决方案的制造商,业务已遍布全球65多个国家。通过参加INTERPHEX 2026,USA Pack Machines LLC旨在与寻求了解符合当前生产和合规要求的包装技术的制药制造商、工程师和行业利益相关者进行交流。 INTERPHEX以连接科学创新与实际制造应用而闻名。该活动设有技术会议、结构化学习会议以及涵盖开发、加工、包装和分销的广泛展区。USA Pack Machines LLC计划利用此次活动作为契机,就制药制造环境中的运营挑战和不断变化的期望交流观点。 在为期三天的展览期间,该公司将介绍其旨在支持效率、一致性和法规符合性的药品包装系统。公司代表将在展位现场,讨论特定应用需求,并分享为一系列药品生产需求开发的包装解决方案的详细信息。 参加INTERPHEX 2026反映了USA Pack Machines LLC与全球制药制造社区的持续互动。该公司将此次展览视为一个进行专业对话、知识共享和加强行业关系的论坛,以支持制药加工和包装的长期进步。活动信息 活动名称:INTERPHEX 2026 日期:2026年4月21日至23日 地点:美国纽约Jacob K. Javits会议中心 参展商:USA Pack Machines LLC 展位号:1037媒体联系Harikrushna Machines+91-79-48928367Plot No. 513, Phase IV, G.I.D.C, Vatva 来源:Harikrushna Machines Pvt. Ltd.本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, GIC Private Limited made its equity investment in Ascletis Pharma by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
(SeaPRwire) - 时尚领袖B2B平台Fashion Sourcing推出,旨在改变时尚品牌与亚洲制造商之间的服装采购模式,提供简化的定制制造解决方案。满足所有服装需求的服装制造领导者。2026年2月5日纽约州纽约市——由Global Sourcing提供支持的B2B电子商务领域头号领导者Fashion Sourcing,在服装、配饰和纺织品的定制制造方面引领B2B电子商务领域。 作为领先的采购平台,Fashion Sourcing将全球时尚品牌与亚洲顶尖的男装、女装、童装和婴儿装制造商联系起来。我们的平台简化了从设计开发到最终生产的整个采购流程,确保每个步骤的质量和效率。 亚洲强大且领先的纺织基础设施、熟练的劳动力以及多年的服装制造专业知识使其成为采购服装的理想选择。 Fashion Sourcing创始人兼首席执行官Laurent Gabay先生表示:“亚洲是全球制造业领导者,提供广泛的服务和行业,从汽车和电子到软件、家用纺织品、时尚服装、鞋类等等。”我们的平台促进与专门从事男装、女装、童装和婴儿装的经过验证的亚洲制造商更轻松地合作。我们在亚洲各地的每个制造商中心都经过全面验证,从符合全球标准到符合道德制造实践。我们还有实地质量控制团队监控生产,确保所有服装符合确切规格和截止日期。 “我们通过一站式数字平台帮助全球买家从经过验证的亚洲供应商处采购定制制造的商品,并提供端到端的交易支持。Fashion Sourcing通过展示亚洲制造商的实力,改变B2B出口市场体验,”Fashion Sourcing创始人兼首席执行官Laurent Gabay先生表示。我们与众不同的地方在于我们的上市速度。我们拥有完整的基础设施和能力,可以根据关税、贸易战、政府法规等不稳定因素以及其他可能影响服装行业的意外因素,在不同地区促进生产。” 我们敬业的实地质量管理团队确保遵守质量标准和交付时间线。我们建立的全球合作伙伴关系通过集成物流、质量控制和融资服务增强运营。 使用Fashion Sourcing平台,新品牌和现有品牌可以生产高质量产品,提供具有竞争力的价格、灵活的最小订单量和快速打样能力。在竞争激烈的时尚世界中,速度、质量和可靠性决定成功。如果您的品牌想要在全球蓬勃发展,您需要一个能够全球交付、轻松扩展并简化生产的采购合作伙伴。这个合作伙伴就是Fashion Sourcing——连接品牌与全球顶级制造商的领先B2B服装采购平台。值得信赖的制造商全球网络访问中国、印度、越南、孟加拉国、柬埔寨、泰国和巴基斯坦经过验证的供应商和工厂。Fashion Sourcing确保您的品牌从值得信赖的制造商那里获得优质面料、辅料和工艺。上市速度简化一切——从材料采购和样品审批到生产跟踪——让您的系列比竞争对手更快进入市场。灵活且可扩展的解决方案从测试第一个系列的初创公司到全球扩展的成熟品牌,Fashion Sourcing适应您的需求,提供低最小订单量(MOQs)和可扩展的生产,以负责任地增长。端到端品牌支持除了将您与供应商联系起来,Fashion Sourcing还提供全方位服务支持:质量控制、供应商审查、合规性和物流——让您专注于设计和品牌增长。道德与可持续采购消费者关心责任。Fashion Sourcing强调道德制造、可持续实践和透明度,帮助您的品牌保持值得信赖和环保意识。已验证的全球增长与Fashion Sourcing合作的品牌在行业远见者Laurent Gabay的指导下,成功在国际上推出系列、优化生产成本并扩展到新市场。具有竞争力的价格和成本效率利用Fashion Sourcing的批量采购能力和全球供应商网络,在不牺牲质量的情况下降低生产成本——最大化您的利润率。先进技术与实时跟踪使用数字工具实时管理订单、生产和发货,保持供应链每个环节的透明和高效。趋势预测与市场洞察Fashion Sourcing不仅限于生产:品牌可以获得市场趋势、风格洞察和供应商创新,帮助他们设计在全球畅销的产品。风险缓解通过经过审查的供应商、多元化的制造中心和合规检查,Fashion Sourcing将延误、质量问题和全球贸易中断的风险降至最低。定制制造与产品创新从限量版到创新设计,Fashion Sourcing与能够定制服装和配饰的供应商合作,为品牌在市场中提供独特优势。Fashion Sourcing不仅仅是一个采购平台——它是您品牌的增长引擎。全球覆盖、速度、可扩展性、道德实践、成本效率和全方位服务支持确保您的系列更快上市、销售更好并扩展到全球。不要只是采购——明智采购。与Fashion Sourcing一起采购。 如有所有采购需求,请访问我们的网站:媒体联系Fashion-Sourcing 来源:Fashion-Sourcing 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布,覆盖超过6,500个媒体库、86,000名编辑和记者,以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 当前,餐饮行业竞争日趋激烈,行业集中度逐步提升,消费者对食材新鲜度、口味标准化、品牌公信力的要求不断提高,具备核心供应链优势与清晰发展战略的企业愈发凸显竞争韧性。绿茶集团有限公司("绿茶"或"公司",股份代号: 6831.HK)作为休闲中式餐厅行业龙头,凭借优异、完善的供应链体系及前瞻性的国际化布局,成功突破行业发展瓶颈,化解传统餐饮运营痛点,在行业同质化竞争中脱颖而出。独特优秀供应链模式 助力菜品迭代升级提升核心竞争力优秀的供应链是餐饮企业的核心竞争力,是保障菜质量量、控制运营成本、实现规模化拓店的关键支撑,更是餐饮品牌穿越行业周期、实现长效发展的坚实根基。从供应链的演变方面来看,餐饮行业供应链经历了三次重要迭代:第一代供应链以"当地采购+厨房现炒"为核心模式,其劣势在于食材采购分散、难以实现标准化生产,且食材质量参差不齐、溯源体系不完善,无法支撑品牌规模化拓店;第二代供应链升级为"中央厨房+厨房加工"模式,虽在一定程度上解决了标准化问题,但受限于菜品加工模式,难以满足当下消费者对"现做现吃"的新鲜度需求,制约了品牌口碑提升。而绿茶精准把握行业痛点与消费趋势,创新采用第三代供应链模式:头部供应商+数字化冷链+智能厨房,该模式实现了"质量可控、新鲜现炒、口味标准"三者的有机统一,既规避了前两代供应链的核心短板,又兼顾了规模化运营与消费体验,成为行业供应链升级的标杆。在供应商合作层面,绿茶坚持与头部优质供应商深度绑定,构建稳定、高质量的食材供应体系,其供应商主要包括北京古船食品有限公司、正大集团、紫燕食品等行业龙头企业。其中,古船食品是集面粉加工、食品生产、产品研发、粮食储备、粮食贸易、销售服务为一体的大型国有企业,凭借严格的质量管控体系与稳定的产能,为绿茶提供高质量的面制品食材;正大集团成立于1921年,是知名跨国企业,在全球拥有完善的养殖、加工体系,为绿茶提供新鲜、安全的畜禽类食材,双方的深度合作为公司保障了食材质量。仓储物流方面,绿茶搭建了覆盖全国的数字化冷链仓储体系,目前在全国布局8大中心仓,广泛覆盖华南、华北、华东、西南等国内主要消费区域,食材由供应商直接运送至各中心仓后,通过精准分拣、动态管控,再以全程冷链运输的方式,配送到全国各大门店,全程实现食材溯源可查、温度实时监控,确保食材新鲜直达,从源头守住菜品质量底线。与这些头部供应商的深度合作,对绿茶的发展形成了双重赋能,一方面,头部供应商的严格质量管控体系与稳定的产能,让公司的食材供应更具保障,产品溯源体系更加完善,专业化程度持续提升,进一步强化了品牌口碑;另一方面,规模化的集中采购模式有效降低了食材采购成本,同时借助供应商的研发资源,助力绿茶实现菜品迭代升级,持续优化产品结构,提升核心竞争力。以绿茶爆款产品——绿茶烤鸡为例,其全流程运营充分彰显了第三代供应链模式的优势。绿茶先根据市场需求与产品标准,向供应商下达定制化采购订单,明确指定鸡的品种、养殖标准及规格要求;供应商按照订单要求进行标准化订单化养殖,确保鸡的生长环境与质量达标;在满足出栏条件后,利用全自动化生产线完成屠宰、消毒、分拣、清洗等一系列加工流程,严格控制每只鸡的规格,确保产品标准化;全程采用0-4℃冷链运输,送达绿茶对应区域中心仓;中心仓收到食材后,根据各门店订单需求进行快速分拣并发往各大门店;门店收到食材后,严格按照公司制定的SOP标准进行腌制,确保口味统一,当顾客下单后,门店员工将腌制好的冰鲜烤鸡放入定制化智能烤箱,烤箱预设定制化专属烤鸡模式,根据烤箱提示完成操作即可出餐。整个流程既保障了烤鸡的新鲜度与口味标准化,又提升了出餐效率,实现了"标准化生产"与"现做现吃"的完美平衡,成为绿茶深受消费者喜爱的核心原因之一。积极布局国际化市场 商业价值与盈利潜力不断提升在深耕本土市场、持续完善供应链体系的同时,绿茶积极布局国际化市场,开启"本土深耕+海外布局"的双轮驱动发展模式,逐步实现品牌的全球化布局。绿茶的出海布局并非偶然,而是具备深厚的基因与坚实的支撑,一方面,公司创始人王董在从事餐饮服务行业之前,拥有丰富的海外经商经验,深刻洞察到海外中餐市场的巨大潜力,出海基因深深烙印在品牌发展之中;另一方面,公司的战略投资者合众集团是一家总部位于瑞士的全球顶级私募投资管理公司,拥有深厚的全球化资源与海外市场运营经验,其全球化的海外背景为绿茶出海提供了强大的资源支持与专业指导,助力绿茶快速适应海外市场环境,降低出海风险。相较于其他中餐品牌,绿茶出海具备多方面独特优势,在菜品方面,绿茶以"中西融合"为核心定位,打造适配全球消费者口味的融合菜,使其菜品具备广泛的市场适应能力,多款核心菜品已深受海外消费者的喜爱;同时,绿茶拥有经验丰富的菜品研发团队,能够快速筛选、优化适配当地市场的菜品,加快品牌融入当地市场的速度。在门店环境与品牌文化层面,绿茶始终坚持将中国传统文化与江南水乡风格融入门店装修设计,打造兼具东方美学与舒适体验的用餐环境。随着中国文化自信的提升与海外市场对中国传统文化兴趣的持续升温,绿茶独特的装修风格与品牌形象,不仅吸引了大量消费者到店用餐,更收获了广泛的品牌关注,成为中国文化出海的重要载体之一。在运营管理方面,目前海外中餐市场缺乏成规模、标准化的大型连锁品牌,而绿茶作为国内休闲中餐赛道的头部连锁品牌,经过多年的发展,积累了丰富的运营经验,形成了完善的运营管理体系。这种成熟的运营管理能力,是海外中小型中餐品牌无法比拟的核心优势,为公司海外门店的快速复制与稳定运营提供了有力保障。作为绿茶国际化布局的起点,公司于2024年9月在中国香港开设首店后,开启国际化拓店的序幕;截至目前,绿茶已在中国香港及海外市场开设门店共计15家,覆盖中国香港、新加坡、马来西亚、泰国等国家和地区,初步完成了中国香港及东南亚市场的布局,品牌海外影响力逐步提升。值得注意的是,公司境外门店的盈利水平显著高于国内门店,其收入和利润规模往往是国内门店的2.5-3倍左右。以中国香港门店为例,其月均收入稳定在150万-200万的较高水平,门店层面经营利润率约为15%以上,充分体现了绿茶境外布局的商业价值与盈利潜力。未来,绿茶的国际化扩张步伐将持续加快,2026年至少新增开设15家海外门店,主要分布在马来西亚、越南等核心潜力市场国家,预计到2026年底,港澳台及海外门店总数将突破30家,实现规模化布局;同时,2026年的利润将有望占集团新增利润的20%,成为公司核心利润增长点之一,进一步推动公司整体业绩提升。总体而言,绿茶凭借行业领先的供应链体系,深厚的出海基因与独特的竞争优势,积极布局国际市场,打开了全新的成长空间。未来,在供应链持续赋能与国际化布局不断深化的双重优势加持下,公司将持续巩固行业龙头地位,实现本土市场与海外市场的协同发展,具备广阔的成长潜力与发展前景,有望成为引领中式餐饮全球化发展的标杆品牌。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031.There remains a critical need for therapies that offer sustained and comprehensive disease control.As a next-generation selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC.The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12). The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY(R) or placebo. The study results showed that, VELSIPITY(R) demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY(R) was consistent with previous studies, with no new safety signals observed. The study confirms the efficacy and safety of VELSIPITY(R) in this population, with results published in The Lancet Gastroenterology & Hepatology.From a clinical value perspective,VELSIPITY(R) is a once-daily oral therapy with rapid onset of action, strong mucosal healing efficacy, and a favorable safety profile. Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University noted that UC is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system. Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse risk, and supports long-term disease management.“UC treatment in China has long faced limited efficacy, high relapse rates, safety concerns, and inconvenient dosing. Despite available biologics and small-molecule therapies, unmet clinical needs persist,” said Prof. Wu Kaichun of the First Affiliated Hospital of AFMU, principal investigator of VELSIPITY(R)’s Asian clinical trial. “Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management.”“Autoimmune diseases have long-term impacts on patients worldwide, with significant unmet clinical needs persisting both in China and globally,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “The approval of VELSIPITY(R) underscores the clinical value of innovative therapies for UC and reflects Everest Medicines’ sustained commitment to advancing drug development in line with international R&D standards. We look forward to expanding our global reach and providing patients with broader access to innovative treatment options.”“Its approval in China addresses a critical unmet medical need and introduces a novel oral therapy promoting deep mucosal healing,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “We are committed to rapidly commercializing VELSIPITY(R) and working toward its inclusion in the National Reimbursement Drug List to further expand patient access and affordability, benefiting more patients across China.”The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis , VELSIPITY(R) was also included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, with strong recommendations supporting its use for both induction and maintenance of remission in patients with moderately to severely active UC. In 2024, VELSIPITY(R) was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. The localized production project for VELSIPITY(R) was launched at the Jiashan manufacturing site in March 2025, supporting its future commercialization in China.The successful approval of VELSIPITY(R) further strengthens Everest Medicines’ product portfolio in the field of autoimmune diseases and also forms a critical part of the 2030 strategy of the Company. This strategy is built on a dual-engine model of business development partnerships and in-house R&D, aiming to generate predictable value through commercialization while building long-term growth momentum through sustained innovation, thereby supporting pipeline continuity and sustainable development.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle.The Company targets annual revenue exceeding RMB10 billion by 2028, and RMB15 billion by 2030 (including approximately RMB9 billion from the existing pipeline and approximately RMB6 billion from newly in-licensed assets). Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafte.Over the same period, the number of commercial products is expected to exceed 20, including NEFECON(R), VELSIPITY(R), XERAVA(R), Lerodalcibep and MT1013.Industry observers widely expect VELSIPITY(R) to become Everest's next blockbuster product, with analysts projecting peak sales of up to RMB 5 billion. As VELSIPITY(R) realizes its commercial potential, Everest's revenue mix and growth trajectory are expected to strengthen further. Looking ahead, Everest Medicines will continue to focus on therapeutic areas with significant unmet clinical needs. Leveraging its established commercialization capabilities and in-house R&D, the company aims to accelerate the launch of innovative therapies with global competitiveness, drive sustainable growth, and create greater health value for patients and society. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布,中国国家药品监督管理局(NMPA)已批准维适平(R)(精氨酸艾曲莫德片, VELSIPITY(R))的新药上市许可申请(NDA),用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。溃疡性结肠炎是一种病因尚不明确、易复发的慢性肠道炎症性疾病。近年来,中国溃疡性结肠炎发病率持续上升,并呈现年轻化趋势,预计患者人数将由2025年的约98万增长至2031年的约150万。疾病对患者生活质量带来长期负担,临床亟需实现更加稳定、持久的疾病控制。作为新一代高选择性S1P受体调节剂,维适平(R)每日一次口服,可实现快速起效和强效深度黏膜愈合,并具有良好的安全性特征,具备最佳药物(best-in-disease)潜质,为成人溃疡性结肠炎患者提供新的一线治疗选择。据悉,维适平(R)此次获批,是基于亚洲多中心III期注册临床ENLIGHT UC研究(ES101002)的结果和全球III期注册研究ELEVATE UC(包括ELEVATE UC 52和ELEVATE UC 12研究)的结果。ENLIGHT UC研究是迄今完成的最大规模亚洲中重度活动性溃疡性结肠炎患者的III期注册临床研究,总计纳入340名患者。结果显示,维适平(R)治疗组在所有主要和次要疗效终点上均达到统计学显著性与临床意义,且安全性良好。研究结果已发表于国际顶级学术期刊柳叶刀子刊《The Lancet Gastroenterology & Hepatology》。从临床价值来看,维适平(R)凭借每日一次口服的治疗方案,能够快速起效并达到临床缓解,同时还在黏膜愈合和组织学改善等方面疗效显著,同时安全性良好。对此,中华医学会消化病学分会前任主任委员、炎症性肠病学组组长、中山大学附属第一医院消化内科学术带头人、首席专家陈旻湖教授指出,我国目前正处于溃疡性结肠炎发病率和患病率快速上升阶段,该疾病常反复发作,严重影响患者生活质量,对个人、家庭和医疗资源造成沉重负担。实现黏膜愈合有助于更有效地控制症状,降低复发风险,改善患者生活质量。黏膜愈合是国内外临床指南公认的溃疡性结肠炎治疗目标,这不仅关系到疾病的长期症状缓解,也与改善患者生活质量密切相关。维适平(R)亚太临床试验牵头研究者、世界胃肠病组织执委兼司库、亚太地区消化病学会副主席、中华医学会消化病学分会第十、十一届副主委、空军军医大学西京消化病医院吴开春教授指出,长期以来,我国溃疡性结肠炎治疗面临传统疗法疗效有限、给药便捷性差以及不良反应多等诸多局限。已获批的生物制剂和小分子治疗也存在"疗效天花板"及"失应答"等问题。维适平(R)通过调控淋巴细胞迁移,从源头控制肠道炎症,并促进黏膜愈合。在多个临床研究中维适平(R)展现出显著疗效,尤其在快速起效、实现无激素缓解及深度黏膜愈合方面具有明显临床优势。此次获批标志着维适平(R)从临床研究到上市的完整验证,为患者提供创新治疗选择,并推动中重度溃疡性结肠炎管理进入新阶段。云顶新耀董事会主席吴以芳表示:"自身免疫性疾病在全球范围内对患者造成长期而深远的影响,在中国乃至全球范围内,仍存在大量尚未满足的临床需求。维适平(R)的获批不仅体现了创新疗法在溃疡性结肠炎治疗中的临床价值,也彰显了公司坚持以国际研发标准推进创新药物发展的长期战略。我们期待通过持续拓展全球化布局,让更多患者受益于高质量、具有突破性的治疗选择。"云顶新耀首席执行官罗永庆表示: "此次维适平(R)在中国的获批,填补了中重度溃疡性结肠炎治疗领域的重要空白,并为以深度黏膜愈合为目标的创新口服治疗提供了新的选择。公司将加快推进维适平(R)的商业化进程,并积极推动纳入国家医保目录,持续提升创新疗法在中国的可及性和可负担性,让更多患者受益。"值得一提的是,维适平(R)的临床价值已获得多项国际权威指南的充分认可,被先后纳入2024年美国胃肠病协会(AGA)临床实践指南及2025年美国胃肠病学院(ACG)临床指南,并获强烈推荐。此前,该药已于2024年和2025年被列入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录(文件中名称为"伊曲莫德")。目前,维适平(R)已在美国、欧盟以及中国大陆、中国香港、中国澳门、新加坡等多个国家和地区获得新药上市批准。2025年3月,云顶新耀启动维适平(R)嘉善工厂建设项目,为本地化生产及长期可及性提供有力支持。维适平(R)的成功获批,进一步夯实了云顶新耀在自身免疫疾病领域的产品布局,也是公司2030年发展战略的重要组成部分。该战略以"BD合作 + 自主研发"双轮驱动为核心,致力于通过商业化实现确定性价值,同时通过持续创新研发构建长期成长动能,推动管线的延续性与可持续发展。在商业化平台建设上,云顶新耀已布局三款商业化产品,并着力建立全渠道商业化体系及药品全生命周期商业化能力。计划到2028年实现收入规模超过100亿元人民币,而到2030年收入规模超过150亿元人民币(其中现有管线销售收入约90亿元人民币而新引进管线销售收入约60亿元人民币);收入的年复合增长率预计在2025至2030年超过50%,2030年后保持超过15%。同时,商业化产品数量将提升至20款以上,包括耐赋康(R)、维适平(R)、依嘉(R)、乐瑞泊(R)(莱达西贝普)及MT1013等。业内普遍认为,维适平(R)有望成长为云顶新耀又一重磅产品,其销售峰值预计可达50亿元人民币。随着维适平(R)商业化进程的持续推进,公司整体收入结构与成长曲线有望进一步优化。未来,云顶新耀将继续聚焦重大未满足临床需求,持续强化差异化创新管线,加速推进具有国际竞争力的创新疗法落地,助力公司实现可持续成长,并为患者与社会创造更大的健康价值。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
The accolades underscore Malaysia’s leading mineral water brand’s international achievements in their consistent pursuit of quality, excellence and industry leadershipKUALA LUMPUR, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) - Spritzer Berhad (“Spritzer” or “the Company”), Malaysia’s leading natural mineral water brand started the year on a strong note with a repeat of the annual recognition by two prestigious platforms, the Putra Brand Awards 2025 and the Superior Taste Award 2025. These achievements, their 10th and 15th recognition for each award respectively, reinforce Spritzer’s continued efforts and commitment to excellence, innovation and uncompromising standards in delivering high-quality natural mineral water locally and internationally.Spritzer Wins the Gold at the Putra Brand Awards 2025Spritzer was awarded the Gold Award in the Beverage – Non-Alcoholic category at the Putra Brand Awards (PBA) 2025, marking its 10th impressive win in the category, further reaffirming its status as Malaysia’s most trusted natural mineral water brand. The Putra Brand Awards are uniquely consumer-driven, with winners selected solely by Malaysian consumers as the judge of brand excellence across 30 categories. As a genuine reflection of the brand’s enduring consumer affinity, market confidence and brand relevance, the accolade is particularly meaningful.Spritzer’s win as the only mineral water brand amidst other well-loved global beverage brands in Malaysia highlights Spritzer’s competitiveness and firm standing in the national beverage landscape. The award was proudly accepted by Dr. Chuah Chaw Teo, Research and Development (R&D) Director of Spritzer, on behalf of the Company.“Winning the Putra Brand Awards for the 10th year affirms our consistent efforts to keep improving over the years,” said Dr. Chuah. “Behind this recognition lies years of disciplined research and development (R&D), stringent quality control, and continuous improvement across our operations and customer touch points. Our priority has always been to safeguard the integrity of our natural mineral water while innovating responsibly to meet the evolving needs of consumers and businesses.”Photo 1 and 2: Spritzer celebrates its Gold Award in the Beverage - Non-alcoholic Category at The Putra Brand Awards 2025A Superior Triumph in Taste GloballySpritzer’s product excellence was further validated internationally at the Superior Taste Award 2025, a globally respected certification conferred by the International Taste Institute in Brussels, Belgium known for its rigorous, professional sensory evaluation of food and beverage products. In 2025, Spritzer Natural Mineral Water secured the prestigious 3-Star Superior Taste Award for the 10th year, a milestone that continues to build on Spritzer’s 15-year legacy of recognition by the International Taste Institute.This long-term acclaim reflects the brand’s unwavering dedicated to delivering natural mineral water of exceptional quality and taste. It reaffirms Spritzer’s strong product capabilities, from taste profile to mineral composition, and its commitment to upholding stringent international benchmarks, further cementing its dominance in Malaysia’s bottled water sector and boosting consumer assurance across local and global markets.Established in 2005, the International Taste Institute is known for its independent, blind tasting methodology, conducted by a panel of over 250 world-class chefs and sommeliers from more than 20 countries worldwide. Products are assessed against strict sensory criteria and only those achieving a score above 70% are certified with the Superior Taste Award, with distinctions awarded based on performance.Photo 2: Spritzer secured the prestigious 3-Star Superior Taste Award for the 10th year for Spritzer Natural Mineral WaterReinforcing Trust Across Markets and StakeholdersTogether, these two awards signify strong domestic consumer confidence and international endorsement of product quality. Backed by robust R&D processes, consistent quality management and a long-standing heritage rooted in nature, Spritzer continues to demonstrate reliability and leadership in the industry.Dr. Chuah concluded, “These speak to the trust that consumers place in us every day. Spritzer remains committed to protecting the purity of our source, strengthening our innovation pipeline, and continuing to deliver natural mineral water of the highest quality that Malaysians and global consumers can rely on.”Supported by its partners, customers, and dedicated team, the Company will continue to represent Malaysian quality on the global stage.For more high-resolution photos, please download them here.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottle.For more information, visit www.spritzer.com.myFor media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 在全球制造业进入「再工业化」与「数字化重构」并行的新阶段,工业数智化已不再是可选项,而是企业提升长期竞争力的必选项。 卡奥斯物联科技股份有限公司(「卡奥斯」),正是这场产业变革的引领者。根植于海尔集团40余年智能制造积淀与大规模定制模式创新实践,卡奥斯以工业大模型驱动的COSMOPlat平台为核心,早已突破传统解决方案供应商的边界,进化为开放、协同、不断自我进化的工业数字生态的构建者。 1月30日,卡奥斯正式向港交所递交上市申请,旨在通过港股上市,将其工业数智化能力,带向更广阔的全球市场。技术赋能产业:COSMOPlat 引领工业转型升级从行业层面看,工业数智化正处于由「系统建设期」向「平台扩展期」过渡的关键阶段。根据Frost &Sullivan数据,2024年,中国工业数智化解决方案市场规模达到2.0万亿元。 相比一次性交付的项目模式或单一解决方案销售,基于工业大模型与智能体技术的工业互联网平台,能够通过能力沉淀和模型复用,实现跨系统的数据接入与统一治理,获得更高的边际效率与更强的客户黏性,其优势将持续凸显。卡奥斯的核心竞争力,正在于其自主开发的COSMOPlat工业互联网平台,其构建了工业智能软件与智能体应用、工业作系统与工业大脑、物联系统与边缘计算深度融合的一体化技术架构,以端云一体的数据智能与物联网产品及解决方案,全方位赋能企业数智化转型。COSMOPlat平台以工业大模型核心驱动力,该模型为国内首个基于工业互联网平台的工业大模型,依托海尔集团40余年制造业经验、天数工业大数据平台积累的专家模型与高质量多模态数据集研发而成,可支持研发设计、生产制造、运营服务、 双碳管理等主要工业场景的数智化。 基于天智工业大模型,卡奥斯将智能体应用与工业场景充分融合,打造了覆盖3大行业、40余个核心场景的工业智能体,帮助客户缩短研发周期、提高生产效率、降低用能成本。卡奧斯依託工業互聯網平台,將製造業全流程解構為需求交互、研發、營銷、採購、生產、物流、服務七大模塊,把復雜流程封装為可複製、可推廣的工業智能軟件與端雲一體化解決方案,有力支撐跨行業、跨領域推廣應用,实现从「服务单个企业」到「激活整个产业集群」的价值跃升。目前,卡奥斯已与家电、能源化工等行业的一批龙头企业、专精特新企业和园区客户建立战略合作,共同探索基于工业互联网平台的数智化转型新路径,为客户打造17座灯塔工厂,全球数量最多、覆盖行业最广。不仅如此,标杆项目的示范效应还能带动公司快速切入新行业、获得新客户,形成老客户复购与新客户引流的扩散效应,从单一产品的复购延伸至全链条服务,实现从「单点赋能」到「全场景绑定」,增厚公司业绩弹性。 截至2025年9月,卡奥斯已累计链接企业超16万家,其中付费企业达9500余家,生态规模与商业价值同步提升。全球布局:中国方案的世界表达卡奥斯的另一大看点,是其作为中国工业智能化「方案输出者」的全球定位。 作为中国工业互联网平台出海的先行者,卡奥斯正将成熟的数智化模式推向全球,成为中国智造「走出去」的核心载体。截至2025年9月30日,卡奥斯的解决方案已在全球16个国家推广,在美国、新西兰、意大利等国家的70余座工厂成功落地。 在东南亚,其布局的智能控制器研发制造中心正快速渗透当地电子制造产业链; 在北美,凭借服务海尔集团海外家电互联工厂的经验,公司成功切入当地智能家居领域。 卡奥斯全球化布局的独特之处在于,它不是简单的市场扩张,而是一种更高维度的「软实力」出海,即将其在国内经过验证的工业数智化模式进行全球输出。 2025年前3季度,公司海外收入占比超12%,形成稳定的海外增长曲线。更为深远的影响体现在国际标准制定领域。 卡奥斯是首家被IEEE、ISO、IEC和UL四大国际标准组织共同批准主导制定工业互联网和大规模定制国际标准的平台,也是首个被欧洲联邦云(GAIA-X)邀请参与共建平台的非欧盟企业,累计主导、参与制定国际标准12项,国家行业标准98项。 通过将技术优势转化为国际规则,卡奥斯为中国在全球工业数字化领域赢得了重要话语权,为后续全球化扩张铺平道路。卡奥斯赴港上市,恰逢全球制造业加速智能化转型、中国数字经济与实体经济深度融合的关键时期。 凭借以AI技术赋能的工业互联网平台,卡奥斯已积累庞大用户基础,更以中国方案输出模式推进全球化布局,持续拓宽增长边界。 平台能力、生态结构与全球复制经验的叠加,让卡奥斯早已超越单一工业互联网服务商的定位,进化为未来工业生态的构建者和中国智造出海的标杆。随着生态成员的持续扩容、国际标准话语权的深化以及新兴市场的加速渗透,卡奥斯的成长潜力将持续释放。 对于关注中国科技出海与全球制造业复苏的国际资本而言,卡奥斯不仅是分享工业数智化红利的优质标的,更有望凭借中国工业技术与生态模式,在全球工业变革浪潮中书写生态共荣、价值共创的全新篇章。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
All-new Versa VanTOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that Mitsubishi Motors Philippines Corporation (MMPC), a subsidiary of Mitsubishi Motors in the Philippines, began sales of the all-new Versa Van on February 6. The model is an OEM-supplied commercial vehicle by Nissan Motor Co., Ltd. (hereafter, Nissan).The all-new Versa Van offers five-row seating for up to 15 passengers and features a spacious interior optimized for transporting people, supporting a wide range of commercial applications, including shuttle services. Powered by a 2.5-liter inline four-cylinder diesel engine, the model delivers strong torque from the moment of acceleration, ensuring confident performance even when carrying many passengers or driving on steep inclines. With this new model, Mitsubishi Motors aims to strengthen its commercial vehicle lineup in the Philippines and meet customer needs alongside the existing L300 model.As Alliance partners, Mitsubishi Motors and Nissan are pursuing global collaboration in areas such as joint development and production of next-generation pickup trucks, as well as joining forces to drive business expansion in electrified vehicles. The OEM supply of the all-new Versa Van by Nissan for the Philippine market represents a tangible outcome of this collaboration. Mitsubishi Motors has also begun supplying Nissan with the Rogue Plug-in Hybrid for North America and the Navara for Oceania and has been supplying the Livina to the Philippine market since 2022 — an initiative that improves plant utilization and complements model lineups, building a mutually beneficial partnership. Furthermore, Mitsubishi Motors will receive OEM supply of an all-new EV model derived from Nissan’s new LEAF in 2026 and will introduce the model to the North American market in the latter half of the year.Mitsubishi Motors will continue to leverage diverse partnerships to expand its product lineup, strengthen regional operations, and accelerate initiatives that enhance profitability.About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society.For more information on Mitsubishi Motors, please visit the company's website at https://www.mitsubishi-motors.com/en/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Eternal Beauty Holdings Limited (“Eternal Beauty” or the “Group”) (Stock Code: 6883.HK), a pioneer in China’s beauty and fragrance industry, announced its first-ever collaboration with Lane Crawford, a premier luxury department store, to launch an exclusive boutique niche fragrance section at its Harbour City store in Tsim Sha Tsui. The collaboration aims to further advances the Group’s strategy focused on high-margin niche fragrance brands, strengthens its premium brand footprint through an elite retail network, and captures the growing profit opportunities in the niche fragrance for Chinese Mainland and Hong Kong markets.The zone brings together four international niche fragrance brands under the immersive concept of a "Luxury Niche Perfume Street" with European flair, featuring Atkinsons, Clive Christian, Memo Paris and SOLFÉRINO, each presented with its unique style and heritage. Clive Christian and SOLFÉRINO are making their debut in Hong Kong, offering a rare experience to local high-end consumers. By leveraging Lane Crawford’s premium retail network that reaches high-spending customers, the Group effectively enhances brand penetration in the Hong Kong market. This initiative successfully introduces the Group’s portfolio into a core upscale retail destination in Hong Kong, demonstrating the Group’s strengths in channel expansion and retail curation, while further solidifying its brand influence and long-term growth momentum in the niche fragrance portfolio.Brand Introduction:AtkinsonsThe 200-year-old British "Royal Fragrance House" reinvents the rebellion and elegance of 19th-century English gentlemen, transforming historical formulas into a modern, contemporary aura.Clive ChristianThe first exclusive collectors’ boutique in Hong Kong: Clive Christian is a luxury British perfume house that creates the world's finest perfumes. A legacy of British craftsmanship, unparalleled quality in concentration and complexity, unashamedly indulgent and luxurious presentation.Memo ParisMemo Paris is a Parisian fragrance house, see each fragrance as a travel note captured in scent. Preserve memory of a journey to unique destination. Memo Paris sketches a delicate, emotional map of the world: a universe where memories become scents.SOLFÉRINODebuting brilliantly in Hong Kong, SOLFÉRINO is born in Paris, France, the brand draws inspiration from the historic architecture of this City of Lights, showcases French elegance with exceptional craftsmanship and presenting Parisian audacity and creativity.Ms. Wendy Lau, Executive Director of Eternal Beauty and Chairman of the International Fragrance Association, said, “With over 40 years of industry experience, Eternal Beauty has cultivated sharp market vision, distinctive taste, and profound expertise. This enables the Group to accurately identify and introduce brands that align with market trends and carry strong profit potential into the Greater China market, which continues to demonstrate vigorous consumption upgrade momentum. We are thrilled to partner with Lane Crawford, an influential luxury department platform in Asia, to create this exclusive boutique niche fragrance section in Hong Kong’s core luxury shopping district, leveraging the Group’s strengths in niche fragrance brand management and retail channel development. This is not only an important step for the Group to deepen the niche fragrance market, but also a concrete manifestation of our niche fragrance brand expansion strategy. Moving forward, the Group will continue to explore collaborations with top-tier retail partners. By introducing more niche brands with high growth potential, it will strengthen its long-term growth momentum and enhance sustainable profitability in the fragrance market.”Hong Kong's fragrance market continues to benefit from the momentum of the emotional economy, demonstrating relatively resilient growth against the backdrop of a steady recovery in the overall retail sector. In December 2025, the value of total retail sales in Hong Kong increased by 6.6% YoY; according to market’s outlook reports, the total retail sales in Hong Kong are expected to grow by nearly 8% in 2026, reaching approximately HKD 410 billion, indicating a continued recovery in local consumer demand. Ms. Chole Lam, Executive Director and Chief Executive Officer of Eternal Beauty, said, “In recent years, experiential retail and emotional consumption have gradually emerged as new retail trends, with emotional value playing an increasingly significant role in consumer decision-making. The ability to establish emotional resonance with consumers is becoming an important direction for brand expansion and product innovation. Emerging consumption segments, represented by high-end and niche fragrances, are more being regarded as categories that carry emotional value and lifestyle propositions, highlighting their growth potential in the retail recovery process.”Eternal Beauty has established an omni sales channel network over 400 cities across Chinese Mainland, Hong Kong and Macau. The cooperation with Lane Crawford is an important part of the Group’s retail channel strategy, aiming to enhance the consumer experience and sales conversion by leveraging the prime location and high customer traffic of the premium department store.Photo CaptionEternal Beauty and Lane Crawford debut landmark niche fragrance zone, bringing together four international niche fragrance brands under the concept of a "Luxury Niche Perfume Street". The zone immersively showcasing four distinctive and heritage-rich brands: Atkinsons, Clive Christian, Memo Paris, and SOLFÉRINO.Please download more high-resolution photos via link:https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharingAbout Eternal Beauty Holdings LimitedEternal Beauty Holdings Limited is the largest perfume group (apart from brand-owner perfume groups) in China (including Hong Kong and Macau) in terms of retail sales in 2023. It primarily sells and distributes products procured from third-party brand licensors, and deploys market for these brand licensors, offering such services as brand management, and designing and implementing customized market entry and expansion plans for their brands. The Group boasts large and diversified brand portfolios that include not only perfumes, but also color cosmetics, skincare products, personal care products, eyewear and home fragrances. As at 30 September 2025, it conducted product distribution and market deployment for a total of 74 external brands, including Hermès, Van Cleef & Arpels, Chopard, Albion and Laura Mercier, with products in different pricing tiers and of versatile features that meet the differentiated demands of consumers in Chinese Mainland, Hong Kong and/or Macau. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 中国香水产业领航者颖通控股有限公司(「颖通控股」或「集团」)(股份代号:6883.HK)宣布与顶级奢侈品百货连卡佛达成首度合作,于尖沙咀海运大厦连卡佛内设立首个小众香水限定专区,进一步落实集团聚焦高毛利小众香水品牌的发展策略,并透过顶级零售网络深化高端品牌布局,把握中国内地及香港高端香氛市场持续增长所带来的盈利机遇。专区云集四大国际高端香氛品牌,以充满欧洲风情的「高级小众香水街」为概念,沉浸式呈现 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四个各具风格与传承的品牌。Clive Christian 及 SOLFÉRINO 更是首度登陆香港,为本地高端消费者带来独家体验,并藉助连卡佛覆盖高消费客群的优质零售网络,有效提升品牌在香港市场的渗透率,进一步将集团旗下品牌引入香港核心高端零售据点,展现集团在渠道拓展与零售策展方面的实力,巩固于高端香氛市场的品牌影响力及长期增长动能。品牌介绍:Atkinsons拥有二百年历史来自英国的「皇室御用香氛品牌」,重塑十九世纪英伦绅士的叛逆与优雅,将历史配方化为现代摩登气息。Clive Christian香港首间典藏级专柜:源自英国伦敦的 Clive Christian 被誉为「世界最奢华的香水之一」,致敬英国皇室贵族经典与顶级奢华工艺传承,彰显无可比拟永恒优雅的底蕴。Memo Paris来自法国的 Memo Paris 以旅行与记忆为灵感,以香气铭记旅途故事,绘制一幅诗情画意的香氛情感地图,将世界景致汇聚于瓶中。SOLFÉRINO首次于香港耀目登场的 SOLFÉRINO 诞生于法国巴黎,灵感源自这座光之城的历史建筑,以精湛工艺诠释法式优雅,创作前卫而富创意的香气。颖通控股执行董事及国际香氛协会主席刘颕贤女士表示:「凭借四十余年的行业经验,颖通积累了敏锐视野、独到品味与深厚专业知识,得以精准甄选契合市场趋势且具备盈利潜力的品牌,并引入蕴藏巨大消费升级动能的大中华市场。我们很高兴与亚洲具影响力的奢侈品百货连卡佛携手,在香港核心奢侈品商圈打造首个小众香水专区,充分发挥颖通在高端香氛品牌运营与零售渠道布局方面的专长。这不仅是集团深化小众香水市场的重要一步,更是我们高端香氛品牌布局策略的具体实践。未来,集团将持续探索与顶级零售伙伴的合作机会,引入更多具高成长潜力的小众品牌,进一步强化集团在高端香氛市场的长期增长动能与可持续盈利能力。」香港香氛市场持续受惠于情绪经济带动,在整体零售业稳步复苏的环境下,展现出相对强韧的增长势头。2025年12月,香港零售业总销货价值按年上升6.6%;而根据市场展望报告预测,2026年香港零售总额有望增长近8%,达到约4,100亿港元,显示本地消费需求正持续回暖。 颖通控股执行董事兼首席执行官林荆女士表示:「近年,体验式零售和情绪消费渐成为零售新潮流,情绪价值在消费决策中的比重明显提升,能否与消费者建立情绪共鸣,正日益成为品牌拓展与产品创新的重要方向。以高端与小众香氛为代表的新兴消费板块,愈来愈多地被视为承载情绪价值与生活方式主张的品类,显示其在零售复苏进程中的增长潜力。」颖通控股已建立覆盖中国内地、香港及澳门逾400个城市的全渠道销售网络,是次与连卡佛的合作为集团零售渠道升级策略的重要一环,旨在透过高端百货的黄金地段与客流量,提升品牌消费体验与销售转化。图片说明颖通控股与连卡佛合作开设首个小众香水专区,云集四大国际高端香氛品牌,以充满欧洲风情的「高级小众香水街」为概念,沉浸式呈现 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四个各具风格与传承的品牌。请通过此链接下载更多高清图片:https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharing关于颖通控股有限公司颖通控股有限公司是中国(包括香港及澳门)最大的香水集团(除品牌所有者香水集团外,按2023年零售额计),主要从事销售及分销从第三方品牌授权商采购的产品及为该等品牌授权商进行市场部署,例如为其品牌设计及实施定制的市场进入及扩张计划。颖通控股拥有庞大且多元化的品牌组合,不仅包括香水,还包括彩妆、护肤品、个人护理产品、眼镜及家居香氛。截至2025年9月30日,颖通控股为合共74个外部品牌进行产品分销及市场部署,包括 Hermès、Van Cleef & Arpels、Chopard、Albion及Laura Mercier,涵盖多元化的定价层次及功能,迎合中国内地、香港及或澳门消费者的差异化需求。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
TOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Sony Corporation (Sony), Mitsubishi Corporation, ADEKA CORPORATION , CHIMEI Corporation, ENEOS Corporation, Formosa Chemicals & Fibre Corporation, Hanwha Impact Corporation, Idemitsu Kosan Co., Ltd., Mitsui Chemicals, Inc., Neste Corporation, Qingdao Haier New Material Development Co., Ltd., SK Geo Centric Co., Ltd., Toray Industries, Inc., and Toray Advanced Materials Korea Inc. have jointly established the world’s first global supply chain consisting of fourteen companies across five countries and regions for the production of renewable plastics*2 that can be used in Sony’s high-performance audio-visual products. The various plastic materials manufactured through this supply chain are slated for use in Sony’s products that will be launched worldwide.<Overview of the Entire Supply Chain>(1) Production of renewable naphtha — Neste Corporation / (2) Production of renewable styrene monomer — Idemitsu Kosan Co., Ltd. / (3) Production of renewable polystyrene resin — Formosa Chemicals & Fibre Corporation / (4) Production of renewable para-xylene — SK Geo Centric Co., Ltd. / (5) Production of renewable para-xylene — ENEOS Corporation / (6) Production of renewable terephthalic acid — Hanwha Impact Corporation / (7) Production of renewable PET resin — Toray Advanced Materials Korea Inc. / (8) Production of renewable bisphenol-A — Mitsui Chemicals, Inc. / (9) Production of renewable polycarbonate (PC) resin — CHIMEI Corporation / (10) Production of renewable flame retardants — ADEKA CORPORATION / (11) Production of renewable PC/ABS resin — Qingdao Haier New Material Development Co., Ltd./ (12) Molding manufacturers / (13) Design and manufacturing of finished products — Sony CorporationHigh-performance products such as audio-visual equipment involve a wide variety of plastics, resulting in a complex supply chain that makes it difficult to visualize and manage the entire flow from raw materials. Additionally, plastic components that require high performance in terms of flame resistance and optical properties cannot be fully replaced with plastics produced through material recycling*3, hindering the further reduction of virgin fossil-based plastics in such products.To address these challenges, the fourteen companies collaborated to visualize the existing supply chain for Sony’s products, and created a new supply chain that enables the production of multiple types of renewable plastics from biomass resources with a mass balance approach*4. This allows Sony to proactively source raw materials for its products with the quality and properties equivalent to virgin fossil-based plastics. Defining the supply chain helps the companies track and document GHG (Greenhouse Gas) emissions data over the supply chain in a verifiable way, allowing participating companies to leverage the data to advance efforts to reduce their carbon footprint going forward.This initiative involving wide-ranging partners is part of the ‘Creating NEW from reNEWable materials' project, jointly launched by Sony, which aims to achieve zero usage of virgin fossil-based plastics through the introduction of renewable plastics, and Mitsubishi Corporation.Sony, Mitsubishi Corporation, and the supply chain partners will continue to actively promote the introduction of renewable plastics for high-performance products such as audio-visual products.About ProjectProject Introduction Video:https://youtu.be/3ba3t356sHI[About Sony Corporation]Sony Corporation is a wholly-owned subsidiary of Sony Group Corporation, responsible for the Entertainment, Technology & Services (ET&S) business. With the mission to "create the future of entertainment through the power of technology together with creators", we aim to continue to deliver Kando* to people around the world. Sony is actively promoting initiatives to reduce environmental impact as part of the Sony Group’s "Road to Zero" environmental plan, which aims for zero environmental impact by 2050. In this project, Sony will oversee the entire supply chain and promote the utilization of renewable plastics in our products. https://www.sony.co.jp/en/[About Mitsubishi Corporation]Mitsubishi Corporation (MC) is an integrated trading and investment company that develops and operates businesses across multiple industries together with its global network. MC has eight Business Groups that operate across virtually every industry: Environmental Energy, Materials Solution, Mineral Resources, Urban Development & Infrastructure, Mobility, Food Industry, Smart-Life Creation, and Power Solution. Through these eight Business Groups, MC’s activities have expanded far beyond its traditional trading operations to include project development, production, and manufacturing operations, working in collaboration with our trusted partners around the world. In this project, MC plays a comprehensive role in overseeing the supply chain, including credit delivery management, and promoting the introduction of renewable plastics into Sony products. https://www.mitsubishicorp.com/jp/en/[About ADEKA CORPORATION]ADEKA CORPORATION is a manufacturer of valuable materials with over 100 years of history. ADEKA aims to realize a sustainable society by globally expanding valuable materials that enrich people's lives, such as polymer additives that enhance plastic functionality, advanced semiconductor materials, environmental materials, food products, and agrochemicals. In this project, we manufacture flame retardants with biomass characteristics assigned using a mass balance approach. https://www.adeka.co.jp/en/[About CHIMEI Corporation]CHIMEI is a leading high-performance materials company that designs and manufactures advanced polymer materials, synthetic rubbers, and specialty chemicals, delivering innovative and sustainable solutions for industries worldwide. With a commitment to circularity, environmental responsibility, and close client collaboration, CHIMEI supports and partners with global companies to elevate product performance while jointly minimizing environmental impact. In this project, CHIMEI produces polycarbonate resin (PC) with assigned biomass characteristics using a mass balance approach. https://www.chimeicorp.com/en-US[About ENEOS Corporation]At ENEOS Corporation, our network has grown to about 12,000 ENEOS branded service stations across Japan. ENEOS is expanding business to accommodate energy transitions into sources like hydrogen and Synthetic Fuels in addition to petroleum and petrochemical products produced and manufactured at refineries and factories at various locations in Japan. The ENEOS Group aims to achieve both a stable supply of energy and materials and the realization of a carbon-neutral society, based on its commitment of “Supporting ‘today’s normal,’ taking the lead for ‘tomorrow’s normal.’” In this project, ENEOS manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.hd.eneos.co.jp/english/[About Formosa Chemicals & Fibre Corporation (FCFC)]FCFC is a comprehensive chemical company that manufactures petrochemical products, synthetic fibers, and plastics. FCFC implements a circular economy to achieve both environmental protection and industrial development, working on the development of green chemicals and the expansion of reusable materials. In this project, FCFC manufactures polystyrene (PS) with assigned biomass characteristics using a mass balance approach. https://www.fcfc.com.tw/[About Hanwha Impact Corporation]Hanwha Impact is a leading petrochemical and investment company, engaged in chemical products and next-generation energy solutions. Hanwha Impact aims to achieve a sustainable society through developing eco-friendly energy solutions and fostering future innovative technologies. In this project, Hanwha Impact produces high-purity terephthalic acid (PTA) with assigned biomass characteristics using a mass balance approach. https://www.hanwhaimpact.com/[About Idemitsu Kosan Co., Ltd.]The Idemitsu Group is engaged in the development, manufacture, and sales of a wide variety areas of Petroleum, Basic Chemicals, High-Performance Materials, Power/Renewable Energy, and in a variety of fields. Idemitsu Kosan is taking on the challenge of an energy transition to help realize a carbon-neutral and circular society by 2050. In the Basic Chemicals business, we are promoting the use of biomass feedstocks and advancing chemical recycling initiatives. In this project, Idemitsu Kosan produces styrene monomer (SM) using a mass balance approach. https://www.idemitsu.com/en/index.html[About Mitsui Chemicals, Inc.]Mitsui Chemicals is a chemical manufacturer that provides solutions for achieving a sustainable society, offering a wide range of products and services from basic chemicals to high-performance materials. Aiming for carbon neutrality by 2050, the company is working to reduce GHG emissions (Scope 1 and 2) and to maximize its contribution to GHG reductions throughout the entire product life cycle. In this project, Mitsui Chemicals produce biomass-derived bisphenol A (BPA) using the mass balance approach. https://jp.mitsuichemicals.com/en/index.htm[About Neste Corporation]Neste (NESTE, Nasdaq Helsinki) creates solutions for mitigating climate change and accelerating a shift to a circular economy. The company is the world’s leading producer of sustainable aviation fuel (SAF), renewable diesel, and renewable and circular solutions for the chemical and plastics industries. In this project, NESTE supplies renewable naphtha made from waste cooking oil and other renewable raw materials. https://www.neste.com/[About Qingdao Haier New Material Development Co., Ltd.]Haier is a global home appliance manufacturer originating, offering a wide range of products including refrigerators and washing machines. Haier New Materials, a subsidiary of the Haier Group, reduces carbon emissions and promotes the construction of a sustainable society by recycling regenerated plastic materials from disassembled home appliances. In this project, Haier produces recycled PC/ABS blended with a flame retardant with assigned biomass characteristics. https://www.haierdawn-plastics.com/[About SK Geo Centric Co., Ltd.]SKGC is a leading chemical company, offering petrochemical products such as olefins, aromatics and polymers. SKGC is upgrading our portfolio to provide more sustainable products in consumer’s daily lives. In this project, SKGC manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.skgeocentric.com/[About Toray Industries, Inc.]Toray Industries, Inc., is a global leader in advanced materials innovation, comprising more than 300 affiliated companies and approximately 48,000 employees worldwide. Since 1926, Toray Industries have continuously expanded our business portfolio—from Fibers & Textiles, to Resins & Chemicals, Films, Electronics & Information Materials, Carbon Fiber Composite Materials, Pharmaceuticals & Medical Products, as well as Water Treatment & Environment. April 2026 marks the 100th anniversary of Toray’s founding. In line with our Corporate Philosophy, “Contributing to society through the creation of new value with innovative ideas, technologies and products,” we will commit to delivering fundamental solutions to global-scale challenges. https://www.toray.com/ [About Toray Advanced Materials Korea Inc.]TAK is a comprehensive chemical manufacturer, offering various products from daily life to high-end industries. With consistent investing and innovation, TAK provides material solutions for climate crisis. In this project, TAK manufactures PET resin and film with assigned biomass characteristics using a mass balance approach. https://www.torayamk.com *1 In the manufacturing of audio-visual products, this initiative is regarded as a “world’s first” in that it visualizes the entire supply chain from raw materials to finished products and converts raw materials to biomass-based materials at mass-production scale.(Based on research conducted by Mitsubishi Corporation. At the time of announcement in Feb. 2026)*2 Plastics made from renewable biomass resources instead of fossil resources.*3 A method of reusing plastic materials by returning used plastics to their original form through physical processes such as crushing, cleaning, and melting, rather than discarding them.*4 This is a method of allocating the characteristics of specific raw materials, such as biomass resources, to a portion of the product based on the input amount of those materials when they are mixed with non-specific raw materials during the distribution and processing stages from raw materials to products.* "Sony", "SONY" logo and any other product names, service names or logo marks used in this press release are registered trademarks or trademarks of Sony Group Corporation or its affiliates. Other product names, service names, company names or logo marks are trademarked and copyrighted properties of their respective owners and/or licensors.* Visual content in this release may be removed without prior notice due to licensing or copyright reasons.* Kando is a Japanese word that roughly translates to the sense of awe and emotion you feel when experiencing something beautiful and amazing for the first time.MaterialityBased on the Three Corporate Principles, which serve as MC’s core philosophy, MC has continued to grow together with society by contributing to the sustainable development of society through its business activities while pursuing value creation. While continuously creating Shared Value guided by the Materiality, a set of crucial societal issues, MC will continue to strengthen its efforts towards sustainable corporate growth. Guided by this Materiality, MC will continue to strengthen its efforts towards sustainable corporate growth. Out of the six material issues relating to “Realizing a Carbon Neutral Society and Striving to Enrich Society Both Materially and Spiritually”, this project’s activities particularly support “Contributing to Decarbonized Societies” and “Promoting Stable, Sustainable Societies and Lifestyles.”Inquiry RecipientMitsubishi CorporationTelephone:+81-3-3210-2171 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
TOKYO and SHANGHAI, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, “Henlius”) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan.Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode that differs from existing anti-PD-1 antibodies. 1 In China, it has been approved for indications such as squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsNSCLC), and esophageal squamous cell carcinoma (ESCC). In the EU, it has been approved for ES-SCLC. It is the world's first anti-PD-1 antibody to be used as a first-line treatment for ES-SCLC.In Japan, Henlius is currently conducting a Phase II bridging clinical trial for ES-SCLC, and plans to submit an application for fiscal year 2026 based on the results of this trial as well as the Phase III clinical trial data that supported approvals for this indication in China and Europe. Furthermore, a Phase III multi-national clinical trial for non-high-frequency microsatellite instability (non-MSI-High) metastatic colorectal cancer is underway, with development for new indications also planned.In Japan, it is estimated that there are approximately 13,000 patients diagnosed with ES-SCLC and about 28,000 patients diagnosed with non-MSI-High metastatic colorectal cancer, both of which are considered to have high unmet medical needs. 2,3,4,5Under the terms of this agreement, Eisai will obtain exclusive rights to commercialize serplulimab in Japan. In addition to ES-SCLC and non-MSI-High metastatic colorectal cancer, Henlius plans to also conduct a clinical trial for perioperative gastric cancer in Japan, and will assume the responsibilities of the Marketing Authorization Holder.Eisai will pay Henlius a contractual upfront payment of USD 75 million (approximately JPY 11.6 billion*), in addition to regulatory milestone payments of up to USD 80.01 million (approximately JPY 12.4 billion), and sales milestone payments of up to USD 233.3 million (approximately JPY 36.2 billion). Furthermore, Eisai will pay double-digit royalties based on sales of the product. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2026.“We are pleased to collaborate with Eisai in Japan to advance the development of serplulimab in this important market,” said Dr. Jason Zhu, CEO of Henlius. “Serplulimab has demonstrated its potential across multiple tumor types through global clinical development and regulatory approvals, and Japan represents a critical step in its international journey. By combining Henlius’ innovation capabilities with Eisai’s deep local expertise, we aim to support the efficient development of serplulimab and address unmet medical needs for patients in Japan.”“Serplulimab is an anti-PD-1 monoclonal antibody that has been developed with high priority for indications with significant unmet medical needs, including ES-SCLC, and has already obtained approval for multiple indications in China and the EU. We anticipate that it will also become a promising treatment option in Japan for ES-SCLC and non-MSI-high metastatic colorectal cancer, for which development is underway, as well as for other intractable cancers,” said Toshihiko Yusa, Executive Officer and Head of Japan Business at Eisai. “Eisai will make every effort, in cooperation with Henlius, to deliver serplulimab to patients as soon as possible.”* Converted at an exchange rate of USD 1 = JPY 155MEDIA CONTACTSEisai Co., Ltd. Public Relations DepartmentTEL: +81 (0)3-3817-5120Shanghai Henlius Biotech Inc.Janice Hanjiayi_han@henlius.comBella Zhouwenting_zhou@henlius.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Shanghai Henlius Biotech Inc.Venus Hu junyan_Hu@henlius.com About SerplulimabSerplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) is an anti-PD-1 monoclonal antibody first developed by Shanghai Henlius Biotech, Inc. (“Henlius”), and launched in China in 2022. It has been approved by the National Medical Products Administration of China for indications including squamous non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma, and non-squamous non-small cell lung cancer, and is the world's first anti-PD-1 antibody to be used as a first-line treatment for ESSCLC. It has been approved for the treatment of ES-SCLC in over 40 markets, including the EU, Southeast Asia (Indonesia, Cambodia, Thailand, Singapore, Malaysia), and South America (Peru). Henlius is actively promoting the broader use of serplulimab both as a standalone product and in combination with other innovative therapies, including those developed in-house and externally. Furthermore, the company is conducting numerous clinical trials worldwide on therapies for conditions where existing anti-PD-1 antibodies have not yet been used, focusing on indications such as lung cancer and gastrointestinal tumors.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Shanghai Henlius Biotech, Inc.Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across 60 countries and regions worldwide, including seven approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and four products authorized by the European Medicines Agency (EMA), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.References1. Issafras H, Fan S, Tseng C-L, Cheng Y, Lin P, Xiao L, et al. (2021) Structural basis of HLX10 PD1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS ONE 16(12): e0257972. https://doi.org/10.1371/journal.pone.02579722. National Cancer Center Japan, Cancer Information Service, Cancer Statistics (Japanese only) https://ganjoho.jp/reg_stat/statistics/stat/cancer/index.html Last accessed: January 2026.3. Sabari, J., Lok, B., Laird, J. et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14, 549–561 (2017).4. Fujiyoshi K, Yamamoto G, Takenoya T et al. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. Anticancer Res. 2017;37(1):239- 247.5. Cancer Statistics in Japan-2025 https://www.fpcr.or.jp/pdf/pamphlet/cancer_statistics_2025.pdf (P30) Last accessed: January 2026. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com